In June 2022, the Pulsed Field Ablation (PFA) treatment device independently developed by Shanghai Yuanshan Medical successfully completed the first PFA surgery for atrial fibrillation patients at Huaihe Hospital of Henan University. Recently, the patient underwent a follow-up examination at the hospital and all indicators have recovered well.
The patient is a 63-year-old male who has been suffering from recurrent atrial fibrillation. He came to the Cardiovascular Department of Huaihe Hospital in June seeking treatment. After a comprehensive evaluation by the electrophysiology team, it was determined that the patient was suitable for atrial fibrillation pulsed field ablation. The surgery was performed under local anesthesia and with careful preoperative preparation, it was successfully carried out. In this follow-up examination, the patient's major cardiac indicators have improved, especially the diameter of the left and right atria has returned to normal, and the electrocardiogram has shown a normal sinus rhythm.
According to Professor Zhang Han from the Cardiovascular Department of Huaihe Hospital, Huaihe Hospital is one of the earliest electrophysiology centers in the country to carry out atrial fibrillation pulsed field ablation. Since the first pulsed field ablation surgery was performed using the pulsed field ablation treatment device on June 9, 2022, the hospital has completed four surgeries, solving the "heart" troubles of these patients with atrial fibrillation and receiving unanimous praise from patients and their families.
Atrial fibrillation is a common type of arrhythmia in clinical practice. With the aging of the population, the incidence of atrial fibrillation is increasing, and the number of thromboembolic events and complications of acute heart failure caused by atrial fibrillation is also increasing year by year, which has brought enormous economic and psychological burden to the whole society.
How to adopt safer and more convenient methods to treat atrial fibrillation has become a focus and difficulty in the clinical work of many cardiovascular doctors. Currently, Huaihe Hospital routinely carries out atrial fibrillation radiofrequency ablation, cryoballoon ablation, left atrial appendage closure, and pulsed field ablation, which have brought more safe and effective options for atrial fibrillation patients.
(part of the text is reprinted from Wechat public account: Huaihe Heart)
Alpmed is a high-tech innovative medical enterprise that focuses on the research, development, manufacturing, and production of medical devices. The company has gathered a group of high-quality scientific and technological talents from Nankai University, Tianjin Medical University, and the Biomedical Engineering Research Institute of the Chinese Academy of Medical Sciences, and established a team with strong R&D and industrialization capabilities. Since its establishment in 2014, the company has always focused on high-end medical equipment, investing over 100 million yuan in the malignant tumor treatment and cardiovascular treatment product directions. Among them, the High Voltage Steep Pulse Minimally Invasive Therapeutic system has obtained NMPA approval and CE certification, and in July 2021, it obtained a Class III medical device registration certificate for the treatment of malignant liver cancer tumors in the irreversible electric perforation field. The pulse field ablation treatment device for cardiac electrophysiological treatment has obtained national proprietary technology authorization, conducted multicenter clinical trials in more than ten hospitals nationwide, and in February 2022, it passed the special approval for innovative medical devices by the National Medical Products Administration, becoming a PFA product approved for innovative medical treatment.
Membership
